SOHO 2023 | CARTITUDE-1 final results: PFS of cilta-cel in patients with heavily pre-treated R/R myeloma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, summarizes the final results of the CARTITUDE-1 study (NCT03548207) which led to the approval of ciltacabtagene autoleucel (cilta-cel) in patients with heavily pre-treated relapsed/refractory (R/R) multiple myeloma. Dr Lin comments on the impressive progression-free survival (PFS) observed following a single dose of this CAR-T product. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bluebird Bio: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Legend: Consultancy; Juno: Consultancy; Celgene: Consultancy, Research Funding; Novartis: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Gamida Cell: Consultancy; Takeda: Research Funding; Vineti: Consultancy; Sorrento: Consultancy; Merck: Research Funding.
